Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2706-2711

  DeNardo, Gerald L ^a,c   Lamborn, Kathleen R ^b   Goldstein, Desirée S ^a   Kroger, Linda A ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

Leukemia; Lym 1; Lymphoma; Radioimmunotherapy; Survival

Indexed keywords

IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CU 67; MONOCLONAL ANTIBODY I 131; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 0031471674     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2706::aid-cncr49>3.0.co;2-d     Document Type: Conference Paper

References (21)

1. DeNardo S, DeNardo G, O'Grady L, Macey D, Mills S, Epstein A, et al. Treatment of a patient with B-cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 1987;2:49-53.
2. DeNardo S, DeNardo G, O'Grady L, Levy N, Mills S, Macey D, et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibod Immunoconjug Radiopharm 1988;1:17-33.
3. Goldenberg D. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131 labeled LL2 monoclonal antibody. J Clin Oncol 1991;11:548-64.
4. Czuczman M, Straus D, Divgi C, Graham M, Garin-Chesa P, Finn R, et al. Phase 1 dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993;11:2021-9.
5. Kaminski M, Zasadny K, Francis I, Milik A, Ross C, Moon S, et al. Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
6. Kuzel T, Rosen S, Zimmer A, Silverstein E, Spies S, Saletan S, et al. A phase 1 escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1. Cancer Biother 1993;8:3-16.
7. Meredith R, Khazaeli M, Plott G, Wheeler R, Russel C, Shochat D, et al. Comparison of diagnostic and therapeutic doses of 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibod Immunoconjug Radiopharm 1993; 6:1-11.
8. Press O. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
9. DeNardo G, Lewis J, DeNardo S, O'Grady L. Effect of Lym1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1994;73:1425-32.
10. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. In: Goldenberg D, editor. Cancer Therapy With Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995:217-27.
11. Lewis J, DeNardo G, DeNardo S. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma 1995; 14:115-20.
12. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancer 1995;346:336-40.
13. Anderson J, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
14. Weiss GB, Bunce H, Hokanson JA. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. Controlled Clin Trials 1983;4:43-52.
15. Oye RK, Shapiro MF. Reporting results from chemotherapy trials. Does response make a difference in patient survival? JAMA 1984;252:2722-5.
16. Epstein A, Marder R, Winter J, Stathopoulos E, Chen F, Parker J, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987:47:830-40.
17. DeNardo S, Peng J, DeNardo G, Mills S, Epstein A. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Int J Rad Appl Instrum [B] 1986;13:303-10.
18. Kukis D, DeNardo G, DeNardo S, Mirick G, Miers L, Greiner D, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995;55:878-84.
19. DeNardo G, Lamborn K, DeNardo S, Goldstein D, Dolber-Smith E, Kroger L, et al. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. Cancer Res 1995;55:5893-8.
20. SAS Institute. SAS/STAT Users Guide. Version 6.08. Cary, NC: SAS Institute Inc., 1994.
21. Buyse M, Staquet M, Sylvester R. Cancer clinical trials: methods and practice. New York: Oxford University Press, 1984:362.